
50 Years of Expertise in Pharma & Healthcare
Europe-wide contract logistics for pharmaceuticals and healthcare - Loxxess and Michael Kuhn each bring 25 years of experience to the table - what does that mean?

Europe-wide contract logistics for pharmaceuticals and healthcare - Loxxess and Michael Kuhn each bring 25 years of experience to the table - what does that mean?

Curia has completed a $4 million upgrade to its sterile API manufacturing suites in Valladolid, Spain, to enhance product quality, safety, and regulatory compliance.

The strategic partnership combines Merck's expertise in organoids with Promega's assay technologies.

Hovione has completed a $100 million investment to double spray-drying capacity and expand its East Windsor, New Jersey site, positioning the facility to meet growing US demand.

SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.

Abzena, an end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial license to one of Abzena’s mAbs..

Aenova will install an additional filling and manufacturing line at the Latina, Italy, site. This expansion is an important step to meet the increasing global demand for the production of biologics.

The collaboration aims to accelerate the development of IFF's Designed Enzymatic Biomaterials technology platform and next-gen enzyme technologies for applications in cleaning and personal care products.

Investments will bolster clinical and commercial capacity in US and Europe facilities for injectable and oral solid dose packaging, and sterile filling.

Cambrex announced a $120 million investment to expand its API manufacturing capacity at its Charles City, Iowa, facility by 40%.

The investment will focus on developing gelatin and HPMC facilities, creating over 200 new jobs, and strengthening ACG’s 25-year presence in the US, with operations expected to begin in early 2027.

The ECA Foundation, one of the most important not-for-profit organizations for regulatory expertise in the pharmaceutical industry, aims to become the largest independent GMP/GDP organization in the world.

Part 3: Seven Theses for successful Digitalization in Pharma

Effective and insightful solutions to the most pressing supply chain challenges facing pharmaceutical companies today.

Part 2: Digital transformation - 10 Years after the Start of Pharma 4.0

Part 1: Building a Business Case for Pharma 4.0

October 15, 2025 | Join us for a dynamic virtual event where science meets strategy.

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.

Pfizer to acquire Metsera, a New York, NY-based clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

Prange Pharma is taking over a production site from MSD Animal Health in Aprilia, Italy. A new center for contract manufacturing in the field of animal health products is to be established there.

Acquisition supports Roche’s strategy as it enhances the company’s portfolio in cardiovascular, renal, and metabolic diseases (CVRM) and offers optionality for future combination development.

Includes $1.2 billion in manufacturing facilities, AI, and advanced digital technologies, creating hundreds of highly skilled US jobs.

The pharmaceutical industry has faced significant margin pressures due to rising energy costs, inflation, and geopolitical disruptions.

Amid global uncertainty, Bayer Pharma, led by Stefan Oelrich, pursues strategic transformation to boost resilience, drive innovation, and secure sustainable growth in a changing healthcare landscape.

LGC Group has inaugurated a CAD$100 million (€61.5 million) Organic Chemistry Synthesis Centre of Excellence in Vaughan, Canada.

How pharma & biotech company transformed warehouse capacity planning for strategic growth

New Bay Area building marks significant progress as part of Gilead's $32 billion US investment.

The $700 million project is part of Genentech and Roche’s $50 billion investment in U.S. manufacturing, infrastructure and R&D

CDMO Cambrex announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts

CDMO Hongene Biotech has entered a non-exclusive licensing agreement with the UMass Chan Medical School to produce and supply extended nucleic acid (exNA) monomers and exNA-modified oligonucleotides for research use.

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).

The pharmaceutical industry is evolving due to new regulations and technological developments. Distributors like Biesterfeld play a central role in supporting manufacturers in their daily operations.

AbbVie announced a $195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic active pharmaceutical ingredient (API) production in the US.

Ofichem, a European CDMO specialising in high-quality active pharmaceutical ingredients (APIs) and integrated drug development and manufacturing services, has acquired Meribel Pharma Solutions’ site in Uppsala, Sweden.

Boehringer Ingelheim recorded positive growth in the first half of 2025 with an increase in Group sales of 6.3% to € 14 billion.